Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 0 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Attention Deficit Disorders | 1 |
| Databases | 1 |
| Drug Therapy | 1 |
| Epilepsy | 1 |
| Hyperactivity | 1 |
| Incidence | 1 |
| Patients | 1 |
| Risk | 1 |
| Seizures | 1 |
| Symptoms (Individual… | 1 |
Source
| Developmental Medicine &… | 1 |
Author
| Allen, Albert J. | 1 |
| Ball, Susan | 1 |
| Bangs, Mark E. | 1 |
| Dunn, David | 1 |
| Edison, Timothy | 1 |
| Holdridge, Karen Chilcott | 1 |
| Jin, Ling | 1 |
| Wernicke, Joachim F. | 1 |
| Zhang, Shuyu | 1 |
Publication Type
| Journal Articles | 1 |
| Reports - Research | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
What Works Clearinghouse Rating
Peer reviewed
Direct linkWernicke, Joachim F.; Holdridge, Karen Chilcott; Jin, Ling; Edison, Timothy; Zhang, Shuyu; Bangs, Mark E.; Allen, Albert J.; Ball, Susan; Dunn, David – Developmental Medicine & Child Neurology, 2007
The comorbidity of seizures, epilepsy, and attention-deficit-hyperactivity disorder (ADHD) prompted the examination of whether atomoxetine use for ADHD is associated with an increased risk of seizures. Seizures and seizure-related symptoms were reviewed from two independent Eli Lilly and Company databases: the atomoxetine clinical trials database…
Descriptors: Epilepsy, Incidence, Seizures, Hyperactivity
